Recursion Pharmaceuticals Inc vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45.69. The key difference: Vanguard Global ex-US Real Estate Index Fd ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | VNQI | |
|---|---|---|
Market Cap | $1.53B | — |
Sector | Health | — |
52-Week High | $6.79 | $50.76 |
52-Week Low | $2.84 | $43.26 |
Enterprise Value | $946.50M | — |
Trailing returns across standard periods
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →